Magnetic Resonance - Technology Information Portal Welcome to MRI Technology••
Info
  Sheets


Out-
      side
 



 
 'Alliance Pharmaceutical Corp.' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Alliance Pharmaceutical Corp.' found in 1 term [] and 1 definition []
1 - 2 (of 2)     
Result Pages : [1]
MRI Resources 
Software - Patient Information - Nerve Stimulator - Veterinary MRI - Supplies - Universities
 
Alliance Pharmaceutical Corp.MRI Resource Directory:
 - Manufacturers -
 
www.allp.htm

California-based research and development company. Alliance has several patents regarding "microbubble" compositions such as Imagent® that are intended to enhance ultrasound imaging and Imagent GI as a gastrointestinal MRI contrast agent. Another product is Oxygent™, a synthetic "blood substitute".


Product Information
TRADE NAME
(LOCAL DISTRIBUTION)
FOR SALE FOR SALE /
DEVELOPMENT
DEVELOPMENT
Imagent GI

Contact Information
MAIL Alliance Pharmaceutical Corp.
6175 Lusk Blvd.
San Diego, CA 92121
USA
PHONE +1-858-410-5200
FAX +1-858-410-5161
E-MAIL corpcom@allp.com
ONLINE www.allp.com

spacer
 
• Share the entry 'Alliance Pharmaceutical Corp.':  Facebook  Twitter  LinkedIn  
 
Further Reading:
  Basics:
Slumping MRI market prompts Alliance to halt GI contrast agent effort
Wednesday, 28 September 1994   by www.searchmedica.com    
MRI Resources 
Lung Imaging - Corporations - Education - Contrast Enhanced MRI - Artifacts - Raman Spectroscopy
 
Imagent GIInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Perflubron® is a perfluorochemical for use as an oral contrast agent. Due to its insolubility in water it does not mix with intestinal secretions; thus bowel lumina appear homogeneously dark on MR images when Perflubron® replaces bowel contents. Filled bowel loops appear black with all pulse sequences because the contrast agent lacks mobile protons.
It is commercially available as Imagent GI. Because rapid transit through the gastrointestinal tract it reaches the rectum within 30 to 40 minutes in most patients. MR imaging of the upper abdominal region should begin within 15 minutes and of the pelvic region 15 to 60 minutes after ingestion of perflubron.
See also Classifications, Characteristics, etc.

Drug Information and Specification
NAME OF COMPOUND Perfluoroctylbromide
DEVELOPER Alliance
CENTRAL MOIETY
CONTRAST EFFECT Negative enhancement
RELAXIVITY Proton density reduction, signal void
PHARMACOKINETIC Gastrointestinal
OSMOLALITY
CONCENTRATION Water immiscible liquid
DOSAGE 9 mL per kg of body weight
PREPARATION Finished product
INDICATION Bowel marking
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Bottle of 200cc
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
USA Imagent GI® for sale Alliance Pharmaceutical Corp.

spacer

• View the DATABASE results for 'Imagent GI' (3).Open this link in a new window

 
Further Reading:
  News & More:
Slumping MRI market prompts Alliance to halt GI contrast agent effort
Wednesday, 28 September 1994   by www.searchmedica.com    
MRI Resources 
Case Studies - Most Wanted - Non-English - Safety Training - Cardiovascular Imaging - Diffusion Weighted Imaging
 
     1 - 2 (of 2)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



Acoustic Noise Reduction (Silent, Quiet, etc.) :
cannot get better 
is in its first steps 
is done by earplugs, headphones 
must get better 
is bad, I miss something 
is unnecessary 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • 
Copyright © 2003 - 2018 SoftWays. All rights reserved. [ 21 May 2019]
Terms of Use | Privacy Policy | Advertising
 [last update: 2018-03-08 05:11:00]